Stockreport

Regeneron Pharmaceuticals beats top-line and bottom-line estimates; initiates FY26 outlook [Seeking Alpha]

Sanofi - American Depositary Shares  (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
PDF Fourth quarter 2025 Dupixent ® global net sales (recorded by Sanofi) increased 34% to $4.9 billion versus fourth quarter 2024. Fourth Recommended For You Mo [Read more]